Marco Krengli1, Tiziana Cena2, Thomas Zilli3, Barbara A Jereczek-Fossa4, Berardino De Bari5, Salvador Villa Freixa6, Johannes H A M Kaanders7, Sara Torrente8, David Pasquier9, Claudio V Sole10, Myroslav Lutsyk11, Fazilet O Dincbas12, Yacob Habboush13, Laura Fariselli14, Tatiana Dragan15, Brigitta G Baumert16, Kaouthar Khanfir17, Gamze Ugurluer18, Juliette Thariat19. 1. Dept. of Radiation Oncology, University Hospital, Novara, Italy; Dept. of Translational Medicine, University of Piemonte Orientale, Novara, Italy. Electronic address: marco.krengli@med.uniupo.it. 2. Dept. of Translational Medicine, University of Piemonte Orientale, Novara, Italy. 3. Dept. of Radiation Oncology, Geneva University Hospital, Switzerland. 4. Dept. of Oncology and Hemato-Oncology of University of Milan, Italy; Dept. of Radiation Oncology of European Institute of Oncology IRCCS, Milan, Italy. 5. Dept. of Radiation Oncology, University Hospital "Jean Minjoz", Besançon, France; Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne (UniL), Lausanne, Switzerland. 6. Catalan Institute of Oncology, Badalona, Spain; Institut Oncologic Teknon, Universitat Autònoma de Barcelona, Spain. 7. Dept. of Radiation Oncology, Radboud University Medical Center, Nijmegen, The Netherlands. 8. Dept. of Radiation Oncology, University Hospital, Novara, Italy. 9. Dept. of Radiation Oncology, Centre O. Lambret, Lille, France. 10. Dept. of Radiation Oncology, Clinica Instituto de Radiomedicina, Santiago, Chile; Faculty of Medicina, Universidad Diego Portales, Santiago, Chile. 11. Dept. of Radiation Oncology, Rambam Medical Center, Haifa, Israel. 12. Dept. of Radiation Oncology, Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Turkey. 13. Dept. of Radiation Oncology, Mayo Clinic, Jacksonville, USA. 14. Radiotherapy Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta Milan, Italy. 15. Dept. of Radiation Oncology, Institut J.Bordet, Brussels, Belgium. 16. Dept. of Radiation-Oncology of MediClin Robert-Janker-Clinic, Bonn, Germany; Dept. of Radiology, Radiation-Oncology, University Hospital, Bonn, Germany. 17. Dept. of Radiation Oncology, Centre Hospitalier du Valais Romand, Sion, Switzerland. 18. Dept. of Radiation Oncology, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey. 19. Dept. Of Radiation Oncology, Centre A. Lacassagne, Nice, France; Dept. of Radiation Oncology, Centre F. Baclesse, Caen, France.
Abstract
BACKGROUND AND PURPOSE: The role of radiotherapy (RT) in the treatment of hemangiopericytoma/solitary fibrous tumor (HPC/SFT) is still under debate. We aimed at investigating whether radiotherapy can improve the results in patients operated for extracranial HPC/SFT. MATERIALS AND METHODS: Data from patients with HPC/SFT, treated from 1982 to 2012, were retrospectively reviewed within the Rare Cancer Network framework. Actuarial local control (LC), disease-free survival (DFS), metastasis-free survival (MFS) and overall survival (OS) were calculated with Kaplan-Meyer method. Patient and tumor parameters were analyzed by univariate and multivariate analysis. RESULTS: Of 114 HPC/SFT, 58 (50.9%) occurred in the extremities/superficial trunk and 56 (49.1%) in intra-thoracic/retroperitoneum. Seventy-eight patients (68.4%) underwent surgery only (Sx), and 36 (31.6%) Sx and RT (Sx + RT). Median RT dose was 60 Gy (range 45-68.4 Gy) in 1.6-2.2 Gy fractions. In the extremities/superficial trunk group of patients, actuarial 5-year LC rates were 50.4% after Sx and 91.6% after Sx + RT (p < 0.0001) for LC, and 50.4% after Sx and 83.1% after Sx + RT (p = 0.008) for DFS. In the intra-thoracic/retroperitoneum group of patients, actuarial 5-year rates were 89.3% after Sx and 77.8% after Sx + RT (p = 0.99) for LC, and 73.8% after Sx and 77.8% after Sx + RT (p = 0.93) for DFS. At multivariate analysis, the addition of RT resulted in better LC and DFS in the whole series. The advantage was confirmed for LC in the group of patients affected by extremity/superficial trunk tumors. CONCLUSION: Addition of RT to Sx could improve the prognosis, in terms of LC and DFS, essentially in patients with extremities/superficial trunk tumor locations.
BACKGROUND AND PURPOSE: The role of radiotherapy (RT) in the treatment of hemangiopericytoma/solitary fibrous tumor (HPC/SFT) is still under debate. We aimed at investigating whether radiotherapy can improve the results in patients operated for extracranial HPC/SFT. MATERIALS AND METHODS: Data from patients with HPC/SFT, treated from 1982 to 2012, were retrospectively reviewed within the Rare Cancer Network framework. Actuarial local control (LC), disease-free survival (DFS), metastasis-free survival (MFS) and overall survival (OS) were calculated with Kaplan-Meyer method. Patient and tumor parameters were analyzed by univariate and multivariate analysis. RESULTS: Of 114 HPC/SFT, 58 (50.9%) occurred in the extremities/superficial trunk and 56 (49.1%) in intra-thoracic/retroperitoneum. Seventy-eight patients (68.4%) underwent surgery only (Sx), and 36 (31.6%) Sx and RT (Sx + RT). Median RT dose was 60 Gy (range 45-68.4 Gy) in 1.6-2.2 Gy fractions. In the extremities/superficial trunk group of patients, actuarial 5-year LC rates were 50.4% after Sx and 91.6% after Sx + RT (p < 0.0001) for LC, and 50.4% after Sx and 83.1% after Sx + RT (p = 0.008) for DFS. In the intra-thoracic/retroperitoneum group of patients, actuarial 5-year rates were 89.3% after Sx and 77.8% after Sx + RT (p = 0.99) for LC, and 73.8% after Sx and 77.8% after Sx + RT (p = 0.93) for DFS. At multivariate analysis, the addition of RT resulted in better LC and DFS in the whole series. The advantage was confirmed for LC in the group of patients affected by extremity/superficial trunk tumors. CONCLUSION: Addition of RT to Sx could improve the prognosis, in terms of LC and DFS, essentially in patients with extremities/superficial trunk tumor locations.
Authors: Francisco S Amorim Filho; Flávio M Gripp; Guilherme S Faria; Mateus Capuzzo Gonçalves; Lincoln Miyahira Journal: Cancer Rep (Hoboken) Date: 2022-02-23